Pharmacogenetics of antipsychotic response in the CATIE trial: A candidate gene analysis

Anna C. Need, Richard S.E. Keefe, Dongliang Ge, Iris Grossman, Sam Dickson, Joseph Patrick McEvoy, David B. Goldstein

Research output: Contribution to journalArticle

79 Citations (Scopus)

Abstract

The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 1 Schizophrenia trial compared the effectiveness of one typical and four atypical antipsychotic medications. Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries. For this reason, it is both misleading and unhelpful to perpetuate the current practice of reporting association results for these trials one gene at a time, ignoring the fact that multiple gene-by-phenotype tests are being carried out on the same data set. On the other hand, suggestive associations in such trials may lead to new hypotheses that can be tested through both replication efforts and biological experimentation. The appropriate handling of these forms of data therefore requires dissemination of association statistics without undue emphasis on select findings. Here we attempt to illustrate this approach by presenting association statistics for 2769 polymorphisms in 118 candidate genes evaluated for 21 pharmacogenetic phenotypes. On current evidence it is impossible to know which of these associations may be real, although in total they form a valuable resource that is immediately available to the scientific community.

Original languageEnglish (US)
Pages (from-to)946-957
Number of pages12
JournalEuropean Journal of Human Genetics
Volume17
Issue number7
DOIs
StatePublished - Jan 22 2009
Externally publishedYes

Fingerprint

Pharmacogenetics
Genetic Association Studies
Antipsychotic Agents
Clinical Trials
Genes
Phenotype
Data Mining
Schizophrenia
Research

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Pharmacogenetics of antipsychotic response in the CATIE trial : A candidate gene analysis. / Need, Anna C.; Keefe, Richard S.E.; Ge, Dongliang; Grossman, Iris; Dickson, Sam; McEvoy, Joseph Patrick; Goldstein, David B.

In: European Journal of Human Genetics, Vol. 17, No. 7, 22.01.2009, p. 946-957.

Research output: Contribution to journalArticle

Need, Anna C. ; Keefe, Richard S.E. ; Ge, Dongliang ; Grossman, Iris ; Dickson, Sam ; McEvoy, Joseph Patrick ; Goldstein, David B. / Pharmacogenetics of antipsychotic response in the CATIE trial : A candidate gene analysis. In: European Journal of Human Genetics. 2009 ; Vol. 17, No. 7. pp. 946-957.
@article{8ffc17e7b9f24422b14ce580504e721b,
title = "Pharmacogenetics of antipsychotic response in the CATIE trial: A candidate gene analysis",
abstract = "The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 1 Schizophrenia trial compared the effectiveness of one typical and four atypical antipsychotic medications. Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries. For this reason, it is both misleading and unhelpful to perpetuate the current practice of reporting association results for these trials one gene at a time, ignoring the fact that multiple gene-by-phenotype tests are being carried out on the same data set. On the other hand, suggestive associations in such trials may lead to new hypotheses that can be tested through both replication efforts and biological experimentation. The appropriate handling of these forms of data therefore requires dissemination of association statistics without undue emphasis on select findings. Here we attempt to illustrate this approach by presenting association statistics for 2769 polymorphisms in 118 candidate genes evaluated for 21 pharmacogenetic phenotypes. On current evidence it is impossible to know which of these associations may be real, although in total they form a valuable resource that is immediately available to the scientific community.",
author = "Need, {Anna C.} and Keefe, {Richard S.E.} and Dongliang Ge and Iris Grossman and Sam Dickson and McEvoy, {Joseph Patrick} and Goldstein, {David B.}",
year = "2009",
month = "1",
day = "22",
doi = "10.1038/ejhg.2008.264",
language = "English (US)",
volume = "17",
pages = "946--957",
journal = "European Journal of Human Genetics",
issn = "1018-4813",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Pharmacogenetics of antipsychotic response in the CATIE trial

T2 - A candidate gene analysis

AU - Need, Anna C.

AU - Keefe, Richard S.E.

AU - Ge, Dongliang

AU - Grossman, Iris

AU - Dickson, Sam

AU - McEvoy, Joseph Patrick

AU - Goldstein, David B.

PY - 2009/1/22

Y1 - 2009/1/22

N2 - The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 1 Schizophrenia trial compared the effectiveness of one typical and four atypical antipsychotic medications. Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries. For this reason, it is both misleading and unhelpful to perpetuate the current practice of reporting association results for these trials one gene at a time, ignoring the fact that multiple gene-by-phenotype tests are being carried out on the same data set. On the other hand, suggestive associations in such trials may lead to new hypotheses that can be tested through both replication efforts and biological experimentation. The appropriate handling of these forms of data therefore requires dissemination of association statistics without undue emphasis on select findings. Here we attempt to illustrate this approach by presenting association statistics for 2769 polymorphisms in 118 candidate genes evaluated for 21 pharmacogenetic phenotypes. On current evidence it is impossible to know which of these associations may be real, although in total they form a valuable resource that is immediately available to the scientific community.

AB - The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Phase 1 Schizophrenia trial compared the effectiveness of one typical and four atypical antipsychotic medications. Although trials such as CATIE present important opportunities for pharmacogenetics research, the very richness of the clinical data presents challenges for statistical interpretation, and in particular the risk that data mining will lead to false-positive discoveries. For this reason, it is both misleading and unhelpful to perpetuate the current practice of reporting association results for these trials one gene at a time, ignoring the fact that multiple gene-by-phenotype tests are being carried out on the same data set. On the other hand, suggestive associations in such trials may lead to new hypotheses that can be tested through both replication efforts and biological experimentation. The appropriate handling of these forms of data therefore requires dissemination of association statistics without undue emphasis on select findings. Here we attempt to illustrate this approach by presenting association statistics for 2769 polymorphisms in 118 candidate genes evaluated for 21 pharmacogenetic phenotypes. On current evidence it is impossible to know which of these associations may be real, although in total they form a valuable resource that is immediately available to the scientific community.

UR - http://www.scopus.com/inward/record.url?scp=67649148483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649148483&partnerID=8YFLogxK

U2 - 10.1038/ejhg.2008.264

DO - 10.1038/ejhg.2008.264

M3 - Article

C2 - 19156168

AN - SCOPUS:67649148483

VL - 17

SP - 946

EP - 957

JO - European Journal of Human Genetics

JF - European Journal of Human Genetics

SN - 1018-4813

IS - 7

ER -